About Aldeyra Therapeutics (NASDAQ:ALDX)
Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$2.40 per share
Price / Book2.65
Return on Equity-67.43%
Return on Assets-60.54%
Frequently Asked Questions for Aldeyra Therapeutics (NASDAQ:ALDX)
What is Aldeyra Therapeutics' stock symbol?
Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."
How were Aldeyra Therapeutics' earnings last quarter?
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) posted its earnings results on Thursday, November, 9th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.41) by $0.09. View Aldeyra Therapeutics' Earnings History.
Where is Aldeyra Therapeutics' stock going? Where will Aldeyra Therapeutics' stock price be in 2017?
5 Wall Street analysts have issued 12-month price objectives for Aldeyra Therapeutics' stock. Their forecasts range from $14.00 to $27.00. On average, they expect Aldeyra Therapeutics' stock price to reach $19.40 in the next twelve months. View Analyst Ratings for Aldeyra Therapeutics.
What are Wall Street analysts saying about Aldeyra Therapeutics stock?
Here are some recent quotes from research analysts about Aldeyra Therapeutics stock:
- 1. According to Zacks Investment Research, "Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts. " (11/14/2017)
- 2. Cowen and Company analysts commented, "On its 4Q call, ALDX announced the Feb start of the planned ADX-102 Ph2b allergic." (3/31/2017)
Who are some of Aldeyra Therapeutics' key competitors?
Some companies that are related to Aldeyra Therapeutics include Endocyte (ECYT), Athersys (ATHX), Selecta Biosciences (SELB), Forward Pharma A/S (FWP), Threshold Pharmaceuticals (MTEM), Kindred Biosciences (KIN), Vital Therapies (VTL), Zymeworks (ZYME), Chimerix (CMRX), Vascular Biogenics (VBLT), Cascadian Therapeutics (CASC), Foamix Pharmaceuticals (FOMX), Immune Design Corp. (IMDZ), Minerva Neurosciences (NERV), Tocagen (TOCA), Dicerna Pharmaceuticals (DRNA), Spring Bank Pharmaceuticals (SBPH) and Sorrento Therapeutics (SRNE).
Who are Aldeyra Therapeutics' key executives?
Aldeyra Therapeutics' management team includes the folowing people:
- Todd C. Brady M.D. Ph.D., President, Chief Executive Officer, Director (Age 46)
- Stephen J. Tulipano CPA, Chief Financial Officer, Treasurer (Age 55)
- Scott L Young, Chief Operating Officer (Age 51)
- David J. Clark M.D., Chief Medical Officer
- Ben Bronstein M.D., Director (Age 65)
- Jesse I. Treu Ph.D., Director (Age 70)
- Richard H. Douglas Ph.D., Independent Director (Age 64)
- Martin J. Joyce, Independent Director (Age 61)
- Gary M. Phillips M.D., Independent Director (Age 51)
Who owns Aldeyra Therapeutics stock?
Aldeyra Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (16.14%), Sphera Funds Management LTD. (5.61%) and Bank of New York Mellon Corp (0.10%). Company insiders that own Aldeyra Therapeutics stock include Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc, Stephen J Tulipano and Todd C Brady. View Institutional Ownership Trends for Aldeyra Therapeutics.
Who bought Aldeyra Therapeutics stock? Who is buying Aldeyra Therapeutics stock?
Aldeyra Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Sphera Funds Management LTD. and Bank of New York Mellon Corp. Company insiders that have bought Aldeyra Therapeutics stock in the last two years include Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc, Stephen J Tulipano and Todd C Brady. View Insider Buying and Selling for Aldeyra Therapeutics.
How do I buy Aldeyra Therapeutics stock?
Shares of Aldeyra Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aldeyra Therapeutics' stock price today?
One share of Aldeyra Therapeutics stock can currently be purchased for approximately $6.35.
How big of a company is Aldeyra Therapeutics?
Aldeyra Therapeutics has a market capitalization of $116.62 million. The biotechnology company earns $-18,690,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Aldeyra Therapeutics employs 11 workers across the globe.
How can I contact Aldeyra Therapeutics?
Aldeyra Therapeutics' mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-761-4904 or via email at [email protected]
MarketBeat Community Rating for Aldeyra Therapeutics (ALDX)MarketBeat's community ratings are surveys of what our community members think about Aldeyra Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Aldeyra Therapeutics (NASDAQ:ALDX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$19.40 (205.51% upside)|
Consensus Price Target History for Aldeyra Therapeutics (NASDAQ:ALDX)
Analysts' Ratings History for Aldeyra Therapeutics (NASDAQ:ALDX)
(Data available from 11/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/24/2017||Cantor Fitzgerald||Initiated Coverage||Overweight||$22.00||N/A|
|9/14/2017||Cowen and Company||Reiterated Rating||Outperform||$9.00 -> $14.00||High|
|9/13/2017||Canaccord Genuity||Reiterated Rating||Buy -> Buy||$12.00 -> $27.00||Medium|
|8/9/2017||HC Wainwright||Set Price Target||Buy||$18.00||Low|
|5/31/2017||Stifel Nicolaus||Reiterated Rating||Buy||$16.00||Medium|
|2/29/2016||Janney Montgomery Scott||Reiterated Rating||Buy||N/A|
Earnings History and Estimates Chart for Aldeyra Therapeutics (NASDAQ:ALDX)
Earnings History by Quarter for Aldeyra Therapeutics (NASDAQ ALDX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Aldeyra Therapeutics (NASDAQ:ALDX)
Current Year EPS Consensus Estimate: $-1.39 EPS
Next Year EPS Consensus Estimate: $-1.35 EPS
Dividend History for Aldeyra Therapeutics (NASDAQ:ALDX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Aldeyra Therapeutics (NASDAQ ALDX)
Insider Ownership Percentage: 28.40%
Institutional Ownership Percentage: 40.06%
Insider Trades by Quarter for Aldeyra Therapeutics (NASDAQ ALDX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/19/2017||Life Sciences Maste Perceptive||Major Shareholder||Buy||200,000||$7.25||$1,450,000.00|| |
|6/30/2017||Life Sciences Maste Perceptive||Major Shareholder||Buy||296,007||$4.60||$1,361,632.20|| |
|2/17/2017||Martin Joseph Joyce||Director||Buy||4,444||$4.50||$19,998.00|| |
|2/17/2017||Stephen J Tulipano||CFO||Buy||3,333||$4.50||$14,998.50|| |
|2/17/2017||Todd C Brady||Insider||Buy||22,223||$4.50||$100,003.50|| |
|2/14/2017||Perceptive Advisors Llc||Major Shareholder||Buy||893,025||$4.50||$4,018,612.50|| |
|5/26/2016||Perceptive Advisors Llc||Major Shareholder||Buy||700,000||$5.00||$3,500,000.00|| |
|10/26/2015||Perceptive Advisors Llc||Major Shareholder||Buy||50,000||$6.46||$323,000.00|| |
|10/22/2015||Perceptive Advisors Llc||Major Shareholder||Buy||18,020||$6.47||$116,589.40|| |
|10/20/2015||Perceptive Advisors Llc||Major Shareholder||Buy||37,145||$6.39||$237,356.55|| |
|8/7/2014||Martin Joseph Joyce||Director||Buy||1,000||$3.95||$3,950.00|| |
|8/6/2014||C. Boyd Clarke||Director||Buy||3,000||$3.69||$11,070.00|| |
|5/7/2014||C. Boyd Clarke||Director||Buy||12,500||$8.00||$100,000.00|| |
Latest Headlines for Aldeyra Therapeutics (NASDAQ ALDX)
|Aldeyra Therapeutics, Inc. (ALDX) Given Consensus Rating of "Buy" by Analysts|
www.americanbankingnews.com - November 20 at 1:52 AM
|FY2017 Earnings Estimate for Aldeyra Therapeutics, Inc. (ALDX) Issued By Cantor Fitzgerald|
www.americanbankingnews.com - November 15 at 7:32 AM
|Aldeyra Therapeutics, Inc. (ALDX) Stock Rating Upgraded by Zacks Investment Research|
www.americanbankingnews.com - November 14 at 8:28 PM
|Aldeyra Therapeutics' (ALDX) CEO Todd Brady on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha|
seekingalpha.com - November 10 at 2:31 PM
|Aldeyra Therapeutics, Inc. (ALDX) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS|
www.americanbankingnews.com - November 10 at 12:51 PM
|Aldeyra Therapeutics Announces Third Quarter 2017 Financial Results|
finance.yahoo.com - November 9 at 4:44 PM
|Does Aldeyra Therapeutics Inc’s (ALDX) Debt Level Pose A Serious Problem?|
finance.yahoo.com - November 9 at 4:44 PM
|Aldeyra Therapeutics to Present at the Stifel 2017 Healthcare Conference|
finance.yahoo.com - November 7 at 5:19 PM
|Aldeyra Therapeutics, Inc. (ALDX) Scheduled to Post Earnings on Monday|
www.americanbankingnews.com - November 6 at 5:22 AM
|Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2017 Financial Results|
finance.yahoo.com - November 2 at 4:08 PM
|Cantor Fitzgerald Weighs in on Aldeyra Therapeutics, Inc.'s FY2017 Earnings (ALDX)|
www.americanbankingnews.com - October 27 at 9:44 AM
|Aldeyra Therapeutics (ALDX) to Present Results on ADX-102 in Noninfectious Anterior Uveitis at AUS|
www.streetinsider.com - October 26 at 8:43 PM
|Aldeyra Therapeutics, Inc. (ALDX) Given Consensus Rating of "Hold" by Brokerages|
www.americanbankingnews.com - October 26 at 1:34 AM
|Aldeyra Therapeutics (ALDX) to Present Results on ADX-102 in Noninfectious Anterior Uveitis at AUS - StreetInsider.com|
www.streetinsider.com - October 25 at 9:36 PM
|Aldeyra Therapeutics Announces Presentation of Results on the Efficacy of ADX-102 in Noninfectious Anterior Uveitis at the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting|
finance.yahoo.com - October 25 at 4:34 PM
|UPDATE: Cantor Fitzgerald Starts Aldeyra Therapeutics (ALDX) at Overweight - StreetInsider.com|
www.streetinsider.com - October 24 at 10:15 PM
|Aldeyra Therapeutics (ALDX) Reports Datafor Aldehyde Sequestration as Potential Therapeutic Approach in Succinic ... - StreetInsider.com|
www.streetinsider.com - October 24 at 5:06 PM
|Aldeyra Therapeutics Presents Evidence for Aldehyde Sequestration as a Potential Therapeutic Approach in Succinic Semialdehyde Dehydrogenase Deficiency at the American Society of Human Genetics 2017 Annual Meeting|
finance.yahoo.com - October 24 at 5:06 PM
|Cantor Fitzgerald Initiates Coverage on Aldeyra Therapeutics, Inc. (ALDX)|
www.americanbankingnews.com - October 24 at 4:50 PM
|Head-To-Head Analysis: Aldeyra Therapeutics (ALDX) vs. Its Competitors|
www.americanbankingnews.com - October 24 at 10:44 AM
|Financial Review: Aldeyra Therapeutics (ALDX) and Its Competitors|
www.americanbankingnews.com - October 18 at 2:24 PM
|Aldeyra Therapeutics, Inc. (ALDX) Short Interest Down 45.3% in September|
www.americanbankingnews.com - October 14 at 2:04 AM
|Aldeyra Therapeutics, Inc. (ALDX) Downgraded to Sell at Zacks Investment Research|
www.americanbankingnews.com - October 10 at 8:56 PM
|Aldeyra Therapeutics Announces New Data at 2017 Research & Development Day|
finance.yahoo.com - October 10 at 5:07 PM
|Aldeyra Therapeutics, Inc. (ALDX) Expected to Announce Earnings of -$0.42 Per Share|
www.americanbankingnews.com - October 5 at 6:18 PM
|Aldeyra Therapeutics (ALDX) Presents Novel Data on Efficacy of ADX-102 in Model of Succinic Semialdehyde ... - StreetInsider.com|
www.streetinsider.com - October 5 at 1:07 PM
|Aldeyra Therapeutics Announces Presentation of Novel Data on the Efficacy of ADX-102 in a Model of Succinic Semialdehyde Dehydrogenase Activity at the 2017 American Society of Human Genetics Annual Meeting|
finance.yahoo.com - October 5 at 1:07 PM
|Aldeyra Therapeutics Inc (ALDX): How Does It Impact Your Portfolio?|
finance.yahoo.com - October 2 at 8:35 PM
|/C O R R E C T I O N -- Aldeyra Therapeutics, Inc./|
finance.yahoo.com - October 2 at 3:33 PM
|Aldeyra Therapeutics, Inc. (ALDX) Receives Average Rating of "Buy" from Brokerages|
www.americanbankingnews.com - October 1 at 3:14 AM
|Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Option to ... - PR Newswire (press release)|
www.prnewswire.com - September 23 at 8:50 PM
|Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares|
finance.yahoo.com - September 22 at 2:47 PM
|Life Sciences Maste Perceptive Purchases 200,000 Shares of Aldeyra Therapeutics, Inc. (ALDX) Stock|
www.americanbankingnews.com - September 21 at 10:26 AM
|Aldeyra Therapeutics to Present at the Annual Cantor Fitzgerald Global Healthcare Conference|
finance.yahoo.com - September 20 at 3:39 PM
|Mid-Morning Market Update: Markets Edge Higher; AutoZone Earnings Top Expectations - Benzinga|
www.benzinga.com - September 19 at 3:44 PM
|Aldeyra Therapeutics (ALDX) Prices 3.45M Common Stock Offering at $7.25/Share - StreetInsider.com|
www.streetinsider.com - September 19 at 3:43 PM
|Aldeyra Therapeutics: Secondary Offering Clears Key Overhang - Seeking Alpha|
seekingalpha.com - September 19 at 3:43 PM
|Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock|
finance.yahoo.com - September 19 at 3:43 PM
|Aldeyra Therapeutics: Transitioning Into A Promising Late-Stage Story - Seeking Alpha|
seekingalpha.com - September 18 at 9:10 PM
|Aldeyra Finally Gets The Recognition It Deserves - Seeking Alpha|
seekingalpha.com - September 18 at 9:10 PM
|Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock|
finance.yahoo.com - September 18 at 4:08 PM
| Brokerages Anticipate Aldeyra Therapeutics, Inc. (ALDX) Will Post Earnings of -$0.42 Per Share|
www.americanbankingnews.com - September 17 at 12:30 AM
|Aldeyra Spikes On 'Significant Improvements' In Midstage Dry Eye Study - Seeking Alpha|
seekingalpha.com - September 16 at 3:35 PM
|Today's Research Reports on Trending Tickers: Aldeyra Therapeutics and Arrowhead Pharmaceuticals|
finance.yahoo.com - September 15 at 4:04 PM
|Aldeyra Therapeutics' (ALDX) "Outperform" Rating Reaffirmed at Cowen and Company|
www.americanbankingnews.com - September 14 at 9:08 AM
|Pre-Open Stock Movers 09/13: (SNAK) (ALDX) (JWN) Higher; (DCTH) (AMRK) (WDC) Lower (more...)|
www.streetinsider.com - September 14 at 2:55 AM
|Aldeyra Therapeutics (ALDX) Presents On Dry Eye Disease Phase 2a Results - Slideshow|
seekingalpha.com - September 14 at 2:55 AM
|Aldeyra Therapeutics Inc. (ALDX) Jumped To A 5-Month High On Study Results|
www.rttnews.com - September 13 at 4:53 PM
|Aldeyra Therapeutics (ALDX) Soars: Stock Adds 34.5% in Session|
finance.yahoo.com - September 13 at 4:53 PM
|Aldeyra Therapeutics, Inc. (ALDX) Stock Rating Reaffirmed by Canaccord Genuity|
www.americanbankingnews.com - September 13 at 8:36 AM
Aldeyra Therapeutics (NASDAQ ALDX) Chart for Thursday, November, 23, 2017